Literature DB >> 2571431

Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.

A H van den Meiracker1, A J Man in't Veld, F Boomsma, D J Fischberg, P B Molinoff, M A Schalekamp.   

Abstract

In an attempt to further clarify the mechanism of the maintenance of the antihypertensive effect of beta-adrenoceptor antagonists, the effects of four antagonists with different ancillary properties (acebutolol, atenolol, pindolol, and propranolol) on systemic and renal hemodynamics, body fluid volumes, hormones, and lymphocyte beta-adrenoceptor density were studied in four groups of 10 hypertensive patients. The patients were observed for 3 weeks during active treatment and for 2 weeks after withdrawal of treatment. At the end of the 3-week treatment period, the four drugs had an equal antihypertensive effect (fall in mean arterial pressure, 10-13%). Although renin activity was suppressed (60-70%) by all four drugs, changes in renin or pretreatment values of renin levels were not correlated with the fall in blood pressure. The drugs had no effect on plasma catecholamine concentrations or body fluid volumes. Despite similar antihypertensive effects among the four drugs, the changes in flow and resistance underlying the fall in blood pressure differed considerably. With pindolol, the fall in blood pressure was associated with a fall in vascular resistance (26 +/- 6%), whereas with propranolol, it was predominantly associated with a fall in cardiac output (11 +/- 7%). No significant changes in vascular resistance or cardiac output occurred with atenolol or acebutolol. The changes in renal blood flow and renal vascular resistance occurred in parallel with the changes in cardiac output and systemic vascular resistance. Plasma epinephrine concentration and pretreatment cardiac chronotropic responsiveness to isoproterenol appeared to be inversely correlated with lymphocyte beta-adrenoceptor density (Bmax) (r = -0.41 and -0.43, respectively). With pindolol, Bmax decreased maximally by 39 +/- 6%, and with propranolol, it increased by 51 +/- 17%. With both drugs, significant changes in Bmax were already present 24 hours after treatment. Furthermore, 1 week after withdrawal of treatment with pindolol, Bmax was still down-regulated, and cardiac chronotropic responsiveness was still decreased, whereas 1 week after withdrawal of propranolol, Bmax was still up-regulated, and cardiac chronotropic responsiveness was still increased. No changes in Bmax occurred with the beta 1-selective antagonists acebutolol and atenolol. Thus, despite an equal antihypertensive effect, the four beta-adrenoceptor antagonists appear to have dissimilar effects on cardiac output, renal blood flow, and lymphocyte beta-adrenoceptors. Changes in cardiac output, the circulating blood volume, or angiotensin-mediated vasoconstriction are factors unlikely to be crucial for the antihypertensive effect of beta-adrenoceptor antagonists. Therefore, interference with vasoconstrictor nerve activity through blockade of either central or peripheral prejunctional beta-adrenoceptors could be an alternative explanation of their blood pressure-lowering potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571431     DOI: 10.1161/01.cir.80.4.903

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Up-regulation of beta-adrenoceptors on circulating mononuclear cells after reduction of central sympathetic outflow by clonidine in normal subjects.

Authors:  Y Zoukos; T Thomaides; D V Pavitt; J P Leonard; M L Cuzner; C J Mathias
Journal:  Clin Auton Res       Date:  1992-06       Impact factor: 4.435

2.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Effect of celiprolol therapy on arterial dilatation in experimental hypertension.

Authors:  J P Tolvanen; X Wu; M Kähönen; K Sallinen; H Mäkynen; A Pekki; I Pörsti
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy--echocardiographical follow-up.

Authors:  M Fukunami; K Hashimura; M Ohmori; T Ikeda; K Umemoto; K Kumagai; A Sakai; T Yamada; N Kondoh; T Minamino
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

5.  Effects of chronic pindolol treatment on human myocardial beta 1- and beta 2-adrenoceptor function.

Authors:  R Bjørnerheim; S Golf; V Hansson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

6.  Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats.

Authors:  M Kähönen; H Mäkynen; P Arvola; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

7.  G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans.

Authors:  Heather I Cohn; Yihuan Xi; Stephanie Pesant; David M Harris; Terry Hyslop; Bonita Falkner; Andrea D Eckhart
Journal:  Hypertension       Date:  2009-06-01       Impact factor: 10.190

8.  17β-Estradiol Concentration and Direct β2-Adrenoceptor Inhibition Determine Estrogen-Mediated Reversal of Adrenergic Immunosuppression.

Authors:  Hannah P Priyanka; A Thiyagaraj; G Krithika; R S Nair; W Hopper; S ThyagaRajan
Journal:  Ann Neurosci       Date:  2022-03-03

Review 9.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

10.  β-blockers Reverse Agonist-Induced β2-AR Downregulation Regardless of Their Signaling Profile.

Authors:  Sonia Maccari; Vanessa Vezzi; Federica Barbagallo; Tonino Stati; Barbara Ascione; Maria Cristina Grò; Liviana Catalano; Giuseppe Marano; Paola Matarrese; Caterina Ambrosio; Paola Molinari
Journal:  Int J Mol Sci       Date:  2020-01-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.